AstraZeneca partner Ardelyx dives (again) as lead drug flunks PhII

John Carroll FierceBiotech News

Exec pay critics bristle as Sanofi lines pockets of Viehbacher, Brandicourt

Carly Helfand Sanofi CEOs past and present are in line for big payouts after yesterday's annual meeting, as resolutions passed to line the pockets of ousted skipper Chris Viehbacher ...

Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend

Eric Palmer It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of ...

Collegium swings for a $75M IPO for its abuse-proof painkiller

Damian Garde Months removed from a $ 50 million venture round, Massachusetts biotech Collegium Pharmaceutical is eyeing a $ 75 million IPO to get its abuse-deterrent take on oxycodone ...

Biotech’s boom spells a spike in R&D down payments

Damian Garde The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset ...

One ‘cultural difference’ between Teva and Mylan? Coury’s $22.5M pay wouldn’t fly at Teva

Carly Helfand Since before Teva even made its now-rejected $ 40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a ...

It’s getting mighty crowded in biotech’s hippest neighborhood

Damian Garde Biotech's extended hot streak has put loads of money in the pockets of drugmakers, and nowhere is that clearer than in Cambridge, MA, where the boom has created demand ...

GSK weighing scrapping investor payout to boost dividend instead

Eric Palmer Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from ...

J&J’s 2018 Remicade patent smacked down at PTO again

Tracy Staton Johnson & Johnson said the U.S. Patent and Trademark Office rejected a 2018 Remicade patent for the second time, putting the blockbuster anti-inflammatory's exclusivity ...

Medicines Co. picks up a pair of FDA approvals amid a regulatory turnaround

Damian Garde The Medicines Company won FDA approval for a pair of new acute care treatments, moving on from a series of setbacks with hopes of bagging a third nod next month. FierceBiotech ...
Page 5 of 512345
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS